ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $389 | -11.8% | 18,685 | +1.5% | 0.00% | -25.0% |
| Q2 2023 | $441 | +37.4% | 18,409 | +8.0% | 0.00% | +33.3% |
| Q1 2023 | $321 | +1.6% | 17,042 | -14.3% | 0.00% | 0.0% |
| Q4 2022 | $316 | -99.9% | 19,880 | +3.2% | 0.00% | 0.0% |
| Q3 2022 | $315,000 | +18.0% | 19,258 | +1.6% | 0.00% | +50.0% |
| Q2 2022 | $267,000 | -43.8% | 18,951 | -3.3% | 0.00% | -50.0% |
| Q1 2022 | $475,000 | -51.7% | 19,593 | -53.5% | 0.00% | 0.0% |
| Q4 2021 | $984,000 | +177.2% | 42,128 | +97.1% | 0.00% | +33.3% |
| Q3 2021 | $355,000 | -35.6% | 21,375 | -5.4% | 0.00% | -25.0% |
| Q2 2021 | $551,000 | +3.8% | 22,603 | +9.8% | 0.00% | -80.0% |
| Q1 2021 | $531,000 | -55.6% | 20,585 | -8.0% | 0.02% | -55.6% |
| Q4 2020 | $1,196,000 | +29.6% | 22,380 | -0.0% | 0.04% | +12.5% |
| Q3 2020 | $923,000 | -16.0% | 22,381 | -1.3% | 0.04% | -21.6% |
| Q2 2020 | $1,099,000 | +29.3% | 22,676 | +12.7% | 0.05% | +142.9% |
| Q1 2020 | $850,000 | -4.4% | 20,114 | -3.2% | 0.02% | +31.2% |
| Q4 2019 | $889,000 | +32.1% | 20,775 | +11.0% | 0.02% | +14.3% |
| Q3 2019 | $673,000 | +33.0% | 18,708 | -1.2% | 0.01% | +16.7% |
| Q2 2019 | $506,000 | +9.3% | 18,927 | +9.6% | 0.01% | +9.1% |
| Q1 2019 | $463,000 | +99.6% | 17,262 | +20.3% | 0.01% | +57.1% |
| Q4 2018 | $232,000 | +0.9% | 14,344 | -4.7% | 0.01% | +16.7% |
| Q2 2018 | $230,000 | -51.3% | 15,055 | -28.4% | 0.01% | -53.8% |
| Q1 2018 | $472,000 | -20.4% | 21,021 | +6.8% | 0.01% | -18.8% |
| Q4 2017 | $593,000 | -13.8% | 19,683 | +7.7% | 0.02% | -23.8% |
| Q3 2017 | $688,000 | +37.9% | 18,273 | +2.2% | 0.02% | +31.2% |
| Q2 2017 | $499,000 | +4.0% | 17,881 | +28.0% | 0.02% | -33.3% |
| Q1 2017 | $480,000 | -2.4% | 13,969 | -18.0% | 0.02% | +9.1% |
| Q4 2016 | $492,000 | +3.8% | 17,045 | +14.5% | 0.02% | -21.4% |
| Q3 2016 | $474,000 | +3.0% | 14,892 | +3.2% | 0.03% | +3.7% |
| Q2 2016 | $460,000 | +85.5% | 14,434 | +62.7% | 0.03% | +12.5% |
| Q1 2016 | $248,000 | -9.2% | 8,869 | +15.6% | 0.02% | -29.4% |
| Q4 2015 | $273,000 | -1.1% | 7,669 | -8.2% | 0.03% | +17.2% |
| Q3 2015 | $276,000 | -20.0% | 8,355 | +1.4% | 0.03% | -14.7% |
| Q2 2015 | $345,000 | +41.4% | 8,243 | +10.2% | 0.03% | +13.3% |
| Q1 2015 | $244,000 | +7.0% | 7,477 | +4.3% | 0.03% | -16.7% |
| Q4 2014 | $228,000 | – | 7,170 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |